MiNK治疗报告 其癌症疗法AgenT-797在固态肿瘤中的早期结果有望于11月14日公布。 MiNK Therapeutics reports promising early results for its cancer therapy agenT-797 in solid tumors, set for release Nov. 14.

MINK疗法将于2025年11月14日公布其2025年第三季度财务结果, MiNK Therapeutics will release its third quarter 2025 financial results on November 14, 2025, before market open, followed by a conference call and webcast. 宣布此消息是在SITC年会上发表的最新报告之后,该报告显示了其主要疗法, agenT-797, 能够在晚期的固体瘤中具有持久的免疫复合和早期的抗瘤活性. The announcement follows a late-breaking presentation at the SITC Annual Meeting showing durable immune reconstitution and early anti-tumor activity with its lead therapy, agenT-797, in advanced solid tumors. 现成的 INKT 细胞疗法 正在临床试验中 测试癌症, 移植 -vers -wost疾病, 和免疫机能丧失。 The off-the-shelf iNKT cell therapy is being tested in clinical trials for cancer, graft-versus-host disease, and immune failure. MiNK 的平台旨在连接先天免疫和适应性免疫，并提供针对特定组织的其他项目。 MiNK’s platform aims to bridge innate and adaptive immunity, with additional programs targeting specific tissues. 该公司强调可扩展的、全球可获取的治疗方法,但告诫说,发展时间表、安全和临床利益仍然不确定。 The company emphasized scalable, globally accessible treatments, though it cautioned that development timelines, safety, and clinical benefits remain uncertain.